ProQR Therapeutics (NASDAQ:PRQR) & Capricor Therapeutics (NASDAQ:CAPR) Head-To-Head Contrast

ProQR Therapeutics (NASDAQ:PRQR) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for ProQR Therapeutics and Capricor Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1	1	6	0	2.62
Capricor Therapeutics	1	6	4	0	2.27

ProQR Therapeutics currently has a consensus price target of $7.60, indicating a potential upside of 515.38%. Capricor Therapeutics has a consensus price target of $30.25, indicating a potential upside of 422.90%. Given ProQR Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe ProQR Therapeutics is more favorable than Capricor Therapeutics.

Valuation and Earnings

This table compares ProQR Therapeutics and Capricor Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99 million	7.23	-$47.73 million	($0.46)	-2.68
Capricor Therapeutics	$22.27 million	15.10	-$105.04 million	($2.45)	-2.36

ProQR Therapeutics has higher earnings, but lower revenue than Capricor Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ProQR Therapeutics and Capricor Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-223.51%	-73.83%	-35.14%
Capricor Therapeutics	N/A	-56.60%	-43.97%

Risk & Volatility

ProQR Therapeutics has a beta of 0.2, suggesting that its share price is 80% less volatile than the S&P 500. Comparatively, Capricor Therapeutics has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500.

Insider & Institutional Ownership

32.7% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are held by institutional investors. 8.4% of ProQR Therapeutics shares are held by insiders. Comparatively, 9.2% of Capricor Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.